Bristol Myers Reports Death in Cell Therapy Trial
Bristol Myers Squibb disclosed a patient death due to septic pneumonia in an early stage trial testing its experimental CAR T cell therapy for multiple sclerosis. Shares fell two percent following the safety update as the company reviews ongoing trials.
Insights:
Bristol Myers Squibb disclosed a patient death from septic pneumonia during an early-stage trial of its experimental cell therapy, sending shares down 2% during Friday morning trading. The fatality occurs as pharmaceutical companies face heightened scrutiny over safety data in emerging autoimmune treatments. The setback impacts development timelines for zola-cel, an experimental therapy targeting severe forms of multiple sclerosis.
